Rapid growth and adoption of Xenium Analyzer demonstrates strength of company’s innovation engine, broad commercial reach and operational scale
10x Genomics, Inc., a leader in single cell and spatial biology, announced that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform’s launch. The milestone reflects strong customer demand for the Xenium platform, which is increasingly recognized as the best performing system for in situ analysis.
“We built Xenium so it ‘just works’ in the hands of researchers, and it’s been so rewarding to have our early customers rave about the platform’s ease of use, best-in-class performance and ‘mind-blowing’ data,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “I’m proud of our team for achieving this milestone so quickly, and we’re still just getting started. I firmly believe Xenium has the potential to be one of the most transformative technologies in our industry in decades.”
With the vast majority of the first 100 Xenium shipments already installed, researchers are using the system to successfully analyze a variety of tissues and sample types, including fresh frozen, FFPE and tissue microarrays, and reveal new insights into health and disease.
“The Xenium platform is providing us with unprecedented insight into the molecular pathology of disease at an incredible resolution,” said Dr. Simon Gregory, Professor and Director of the Brain Tumor Omics Program in the Duke University Department of Neurosurgery and Director of the Molecular Genomics Core at the Duke Molecular Physiology Institute. To date, the Gregory Lab has analyzed more than 70 samples on the Xenium platform. “Building on standard panels with custom content has allowed us to begin unraveling the mechanisms within tissues from human and model systems associated with a variety of neurological conditions, including primary and metastatic brain tumors, multiple sclerosis, and behavioral phenotypes in a detailed spatial context.”
Dr. Bo Li, Senior Research Fellow at the Genome Institute of Singapore, said, “Xenium is a state-of-the-art spatial-omics technology that enables researchers to spatially profile RNA transcripts at subcellular resolution within complex tissue systems. What impresses me the most about the Xenium is its ability to generate high quality data within a relatively short period of time.”
The Xenium platform includes a state-of-the-art single cell spatial imager; a diverse menu of curated, customizable and high-quality gene panels; primary and secondary onboard analysis; and free access to Xenium Explorer software for interactive data analysis and visualization.
Dr. Olivia Koues, Managing Director of the Advanced Genomics Core at the University of Michigan, said, “We are thoroughly impressed by the seamless and intuitive workflow that this technology offers and how easily it slotted into our core production environment. The Xenium instrument is proving to be a robust in situ spatial analysis tool, allowing us to readily enhance our capabilities and better support the cutting-edge research being done on campus.”
The system’s combination of differentiated chemistry, sophisticated hardware and robust software was carefully engineered to deliver world-class performance, facilitate routine use and enable novel single cell spatial research applications, including isoform mapping, SNV detection, viral genes and more.
“As a user that has experienced other in situ platforms, I can say that the Xenium is a cut above the rest,” said Dr. Luciano Martelotto, Associate Professor at the University of Adelaide and Head of the Development Laboratory of the Adelaide Centre for Epigenetics at the South Australia ImmunoGENomics Cancer Institute. “It streamlines the process from tissue handling to data interpretation, making it faster and easier to get insights into biology. As it evolves, the ‘Xenium ecosystem’ will become a powerful molecular tool to help glean more than just data and in a fraction of the time.”
SOURCE: PRNewswire